[go: up one dir, main page]

MX2009004051A - Uso de antagonistas de il-1 para tratar gota y pseudo gota. - Google Patents

Uso de antagonistas de il-1 para tratar gota y pseudo gota.

Info

Publication number
MX2009004051A
MX2009004051A MX2009004051A MX2009004051A MX2009004051A MX 2009004051 A MX2009004051 A MX 2009004051A MX 2009004051 A MX2009004051 A MX 2009004051A MX 2009004051 A MX2009004051 A MX 2009004051A MX 2009004051 A MX2009004051 A MX 2009004051A
Authority
MX
Mexico
Prior art keywords
pseudogout
gout
antagonists
treat gout
antagonist
Prior art date
Application number
MX2009004051A
Other languages
English (en)
Inventor
Scott Mellis
Catherine Vicary
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2009004051A publication Critical patent/MX2009004051A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para tratar, inhibir o mejorar la gota, incluyendo gota activa crónica (refractaria), o pseudo gota en un sujeto humano que necesita de ello, que comprenden administrarle a un sujeto que necesita de ello una cantidad terapéutica de un antagonista de interleucina 1 (IL-1), en donde la gota o la pseudo gota son inhibidas o mejoradas. Preferiblemente, el antagonista de IL-1 es la proteína de SEQ ID NO:10 (rilonacept).
MX2009004051A 2006-10-20 2007-10-19 Uso de antagonistas de il-1 para tratar gota y pseudo gota. MX2009004051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85338506P 2006-10-20 2006-10-20
PCT/US2007/022377 WO2008051496A2 (en) 2006-10-20 2007-10-19 Use of il-1 antagonists to treat gout and pseudogout

Publications (1)

Publication Number Publication Date
MX2009004051A true MX2009004051A (es) 2009-05-11

Family

ID=39322920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004051A MX2009004051A (es) 2006-10-20 2007-10-19 Uso de antagonistas de il-1 para tratar gota y pseudo gota.

Country Status (20)

Country Link
US (1) US20080300185A1 (es)
EP (1) EP2124997B1 (es)
JP (1) JP5397948B2 (es)
CN (1) CN101528252B (es)
AU (1) AU2007309470B2 (es)
BR (1) BRPI0718469A2 (es)
CA (1) CA2666629C (es)
DK (1) DK2124997T3 (es)
ES (1) ES2389314T3 (es)
HR (1) HRP20120896T1 (es)
IL (1) IL197832A (es)
MX (1) MX2009004051A (es)
NZ (1) NZ575972A (es)
PL (1) PL2124997T3 (es)
PT (1) PT2124997E (es)
RS (1) RS52538B (es)
RU (1) RU2450824C2 (es)
SG (1) SG175642A1 (es)
SI (1) SI2124997T1 (es)
WO (1) WO2008051496A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
EP2683372B1 (en) * 2011-03-11 2017-07-12 TWI Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
CN105367663A (zh) * 2014-08-31 2016-03-02 复旦大学 一种长效白细胞介素-1受体拮抗剂重组融合蛋白及其制备方法和用途
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN110251659A (zh) * 2019-07-03 2019-09-20 安徽省立医院 一种小剂量白细胞介素2在制备治疗慢性痛风药物中的应用
CN116539880B (zh) * 2022-12-05 2023-12-08 四川大学华西医院 检测代谢物和/或组织蛋白的试剂在制备痛风性关节炎筛查试剂盒中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
US7226553B2 (en) * 2003-07-30 2007-06-05 E. I. Du Pont De Nemours And Company Polymer underwater pelletizer apparatus and process incorporating same
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization
MXPA06014126A (es) * 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
ES2373668T3 (es) * 2004-09-17 2012-02-07 Kissei Pharmaceutical Co., Ltd. Derivado de nucleósido de purina modificado en la posición 8 y uso medicinal del mismo.
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
WO2007077042A1 (en) * 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout

Also Published As

Publication number Publication date
CA2666629A1 (en) 2008-05-02
CN101528252A (zh) 2009-09-09
WO2008051496A8 (en) 2009-07-30
RS52538B (sr) 2013-04-30
RU2009118962A (ru) 2010-11-27
JP2010506936A (ja) 2010-03-04
WO2008051496A2 (en) 2008-05-02
PL2124997T3 (pl) 2013-01-31
CN101528252B (zh) 2014-05-28
CA2666629C (en) 2016-08-16
HRP20120896T1 (hr) 2012-12-31
IL197832A (en) 2014-06-30
JP5397948B2 (ja) 2014-01-22
US20080300185A1 (en) 2008-12-04
AU2007309470B2 (en) 2013-05-23
IL197832A0 (en) 2011-08-01
WO2008051496A3 (en) 2008-10-30
RU2450824C2 (ru) 2012-05-20
NZ575972A (en) 2011-01-28
PT2124997E (pt) 2012-10-24
SI2124997T1 (sl) 2012-11-30
BRPI0718469A2 (pt) 2014-01-21
ES2389314T3 (es) 2012-10-25
EP2124997A2 (en) 2009-12-02
SG175642A1 (en) 2011-11-28
EP2124997B1 (en) 2012-08-08
AU2007309470A1 (en) 2008-05-02
DK2124997T3 (da) 2012-08-27

Similar Documents

Publication Publication Date Title
MX2009004051A (es) Uso de antagonistas de il-1 para tratar gota y pseudo gota.
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
ZA201000149B (en) Glp-1-fc fusion protein formulation
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
NZ588033A (en) Methods of treating a mif-mediated disorder
NZ587297A (en) Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat inflammatory pain
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
SE0200667D0 (sv) Novel use of cytokine inhibitors
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
NO20082636L (no) Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
IL147294A0 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
NO20055187L (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
WO2005027853A3 (en) Method for treating snoring and sleep apnea with leukotriene antagonists
EP1997503A3 (en) Treatment of melanoma with alpha thymosin peptides

Legal Events

Date Code Title Description
FG Grant or registration